Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, diazoxide choline controlled-release (DCCR), a tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into late-stage clinical development. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is based in Redwood City, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLNO
Previous Symbol
CUSIPN/A
Phone650-213-8444
Debt
Debt-to-Equity RatioN/A
Current Ratio4.56
Quick Ratio4.56
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.45 million
Price / Sales23.79
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.38 per share
Price / Book1.17
Profitability
EPS (Most Recent Fiscal Year)($1.35)
Net Income$-15,660,000.00
Net MarginsN/A
Return on Equity-86.69%
Return on Assets-49.44%
Miscellaneous
Employees18
Outstanding Shares21,430,000
Market Cap$34.51 million
OptionableNot Optionable
Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions
What is Soleno Therapeutics' stock symbol?
Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."
When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?
Soleno Therapeutics shares reverse split on Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.
How were Soleno Therapeutics' earnings last quarter?
Soleno Therapeutics Inc (NASDAQ:SLNO) issued its earnings results on Thursday, November, 15th. The company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.11. View Soleno Therapeutics' Earnings History.
When is Soleno Therapeutics' next earnings date?
What price target have analysts set for SLNO?
3 brokerages have issued 12 month price objectives for Soleno Therapeutics' stock. Their forecasts range from $4.00 to $14.00. On average, they expect Soleno Therapeutics' share price to reach $7.3333 in the next year. This suggests a possible upside of 355.5% from the stock's current price. View Analyst Price Targets for Soleno Therapeutics.
What is the consensus analysts' recommendation for Soleno Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soleno Therapeutics.
What are Wall Street analysts saying about Soleno Therapeutics stock?
Here are some recent quotes from research analysts about Soleno Therapeutics stock:
- 1. According to Zacks Investment Research, "Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief. Soleno Therapeutics Inc., formerly known as Capnia Inc., is based in Vancouver, Canada. " (11/8/2018)
- 2. Maxim Group analysts commented, "Soleno announced that it will present two poster presentations on 57 th Athens, Greece. The late-breaking posters will show PK and clinical data as well as the glycemic impact of diazoxide chloride controlled release (DCCR) use, long- term, in Prader-Willi Syndrome (PWS). Conclusion: We view the posters as an opportunity to showcase the potential benefit of DCCR in PWS in the EU. Focus remains on the Phase 3 trial of DCCR in PWS which is enrolling, data in 1H19." (9/17/2018)
Has Soleno Therapeutics been receiving favorable news coverage?
News headlines about SLNO stock have been trending positive this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Soleno Therapeutics earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the company's share price in the immediate future.
Who are some of Soleno Therapeutics' key competitors?
Some companies that are related to Soleno Therapeutics include Fonar (FONR), Electrocore (ECOR), Zynex (ZYXI), Stereotaxis (STXS), Second Sight Medical Products (EYES), Edap Tms (EDAP), IRIDEX (IRIX), Viveve Medical (VIVE), Precision Optics (PEYE), Digirad (DRAD), ENDRA Life Sciences (NDRA), Nexeon Medsystems (NXNN), Aradigm (ARDM), Non-Invasive Monitoring Systems (NIMU) and Vaso (VASO).
Who are Soleno Therapeutics' key executives?
Soleno Therapeutics' management team includes the folowing people:
- Dr. Anish Bhatnagar, Pres, CEO & Director (Age 48)
- Mr. Anthony Wondka, Sr. VP of R&D (Age 56)
- Mr. David D. O'Toole, Consultant (Age 59)
- Mr. Jonathan R. Wolter, CFO & Principal Accounting Officer (Age 68)
- Dr. Neil M. Cowen Ph.D., MBA, Sr. VP of Drug Devel.
Who are Soleno Therapeutics' major shareholders?
Soleno Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc (0.31%). Company insiders that own Soleno Therapeutics stock include Edgar Engleman, Larry N Feinberg and Technology Partners Fund Vii L. View Institutional Ownership Trends for Soleno Therapeutics.
Which institutional investors are buying Soleno Therapeutics stock?
SLNO stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc. Company insiders that have bought Soleno Therapeutics stock in the last two years include Edgar Engleman and Larry N Feinberg. View Insider Buying and Selling for Soleno Therapeutics.
How do I buy shares of Soleno Therapeutics?
Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Soleno Therapeutics' stock price today?
One share of SLNO stock can currently be purchased for approximately $1.61.
How big of a company is Soleno Therapeutics?
Soleno Therapeutics has a market capitalization of $34.51 million and generates $1.45 million in revenue each year. The company earns $-15,660,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. Soleno Therapeutics employs 18 workers across the globe.
What is Soleno Therapeutics' official website?
How can I contact Soleno Therapeutics?
Soleno Therapeutics' mailing address is 1235 RADIO ROAD SUITE 110, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]
MarketBeat Community Rating for Soleno Therapeutics (NASDAQ SLNO)
MarketBeat's community ratings are surveys of what our community members think about Soleno Therapeutics and other stocks. Vote "Outperform" if you believe SLNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
